AR077869A1 - Forma cristalina de tiazolpirrolidin propionamida como inhibidor de la proteina de apoptosis: formulaciones farmaceuticas - Google Patents
Forma cristalina de tiazolpirrolidin propionamida como inhibidor de la proteina de apoptosis: formulaciones farmaceuticasInfo
- Publication number
- AR077869A1 AR077869A1 ARP100102972A ARP100102972A AR077869A1 AR 077869 A1 AR077869 A1 AR 077869A1 AR P100102972 A ARP100102972 A AR P100102972A AR P100102972 A ARP100102972 A AR P100102972A AR 077869 A1 AR077869 A1 AR 077869A1
- Authority
- AR
- Argentina
- Prior art keywords
- propionamide
- crystalline form
- thiazolpirrolidin
- inhibitor
- pharmaceutical formulations
- Prior art date
Links
- 229940080818 propionamide Drugs 0.000 title abstract 4
- 230000006907 apoptotic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- -1 hydrates) thereof Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a la forma cristalina de la (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida, a las sales e hidratos de la misma. También se refiere a una formulacion oral solida de la (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2-oxo-etil)-2-metil-amino-propionamida, a las sales farmacéuticamente aceptables y solvatos (incluyendo hidratos) de la misma, así como a los métodos para el tratamiento mediante su uso. Reivindicacion 1: La forma cristalina de Hemi-hidrato HA de la (S)-N-((S)-1-ciclohexil-2-{(S)-2-[4-(4-fluoro-benzoil)-tiazol-2-il]-pirrolidin-1-il}-2- oxo-etil)-2-metil-amino-propionamida, descrita por la formula (1).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27405109P | 2009-08-12 | 2009-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077869A1 true AR077869A1 (es) | 2011-09-28 |
Family
ID=42937834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102972A AR077869A1 (es) | 2009-08-12 | 2010-08-12 | Forma cristalina de tiazolpirrolidin propionamida como inhibidor de la proteina de apoptosis: formulaciones farmaceuticas |
Country Status (24)
Country | Link |
---|---|
US (4) | US8623385B2 (es) |
EP (1) | EP2464644A1 (es) |
JP (3) | JP2013501751A (es) |
KR (2) | KR20120048008A (es) |
CN (2) | CN105646471A (es) |
AR (1) | AR077869A1 (es) |
AU (4) | AU2010283748A1 (es) |
BR (1) | BR112012003118A2 (es) |
CA (1) | CA2769616A1 (es) |
CL (1) | CL2012000349A1 (es) |
CO (1) | CO6612189A2 (es) |
IL (1) | IL217760A0 (es) |
IN (1) | IN2012DN00858A (es) |
MA (1) | MA33511B1 (es) |
MX (2) | MX351274B (es) |
MY (1) | MY160475A (es) |
PE (2) | PE20121132A1 (es) |
PH (1) | PH12014501890A1 (es) |
RU (1) | RU2671196C1 (es) |
SG (1) | SG177713A1 (es) |
TN (1) | TN2012000026A1 (es) |
TW (1) | TWI607006B (es) |
WO (1) | WO2011018474A1 (es) |
ZA (1) | ZA201200390B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10781205B2 (en) | 2016-04-20 | 2020-09-22 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising RIPK2 inhibitors |
CN108484640B (zh) * | 2018-05-22 | 2020-09-15 | 南京华威医药科技集团有限公司 | 一种抗肿瘤的细胞凋亡蛋白抑制剂 |
HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030119060A1 (en) | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
EP2253614B1 (en) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
CN101146803A (zh) * | 2004-12-20 | 2008-03-19 | 健泰科生物技术公司 | Iap的吡咯烷抑制剂 |
PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2010
- 2010-08-11 US US13/388,149 patent/US8623385B2/en active Active
- 2010-08-11 MY MYPI2012000350A patent/MY160475A/en unknown
- 2010-08-11 IN IN858DEN2012 patent/IN2012DN00858A/en unknown
- 2010-08-11 KR KR1020127006234A patent/KR20120048008A/ko active Search and Examination
- 2010-08-11 KR KR1020187004166A patent/KR20180020315A/ko not_active Application Discontinuation
- 2010-08-11 WO PCT/EP2010/061679 patent/WO2011018474A1/en active Application Filing
- 2010-08-11 RU RU2015155182A patent/RU2671196C1/ru not_active IP Right Cessation
- 2010-08-11 AU AU2010283748A patent/AU2010283748A1/en not_active Abandoned
- 2010-08-11 PE PE2012000206A patent/PE20121132A1/es not_active Application Discontinuation
- 2010-08-11 CN CN201610031620.0A patent/CN105646471A/zh active Pending
- 2010-08-11 PE PE2017000424A patent/PE20170777A1/es not_active Application Discontinuation
- 2010-08-11 CA CA2769616A patent/CA2769616A1/en not_active Abandoned
- 2010-08-11 EP EP10751839A patent/EP2464644A1/en not_active Withdrawn
- 2010-08-11 JP JP2012524227A patent/JP2013501751A/ja not_active Withdrawn
- 2010-08-11 MX MX2013011692A patent/MX351274B/es unknown
- 2010-08-11 MX MX2012001844A patent/MX2012001844A/es active IP Right Grant
- 2010-08-11 SG SG2012004222A patent/SG177713A1/en unknown
- 2010-08-11 CN CN201080035867.0A patent/CN102471331B/zh not_active Expired - Fee Related
- 2010-08-11 BR BR112012003118A patent/BR112012003118A2/pt not_active Application Discontinuation
- 2010-08-12 TW TW099126987A patent/TWI607006B/zh not_active IP Right Cessation
- 2010-08-12 AR ARP100102972A patent/AR077869A1/es not_active Application Discontinuation
-
2012
- 2012-01-18 ZA ZA2012/00390A patent/ZA201200390B/en unknown
- 2012-01-19 TN TNP2012000026A patent/TN2012000026A1/en unknown
- 2012-01-26 IL IL217760A patent/IL217760A0/en unknown
- 2012-02-07 MA MA34608A patent/MA33511B1/fr unknown
- 2012-02-09 CO CO12023091A patent/CO6612189A2/es not_active Application Discontinuation
- 2012-02-10 CL CL2012000349A patent/CL2012000349A1/es unknown
-
2013
- 2013-12-03 US US14/095,313 patent/US9540363B2/en not_active Expired - Fee Related
-
2014
- 2014-08-14 AU AU2014213533A patent/AU2014213533A1/en not_active Abandoned
- 2014-08-20 PH PH12014501890A patent/PH12014501890A1/en unknown
-
2016
- 2016-03-24 JP JP2016060543A patent/JP2016179976A/ja not_active Ceased
- 2016-05-13 AU AU2016203145A patent/AU2016203145A1/en not_active Abandoned
- 2016-11-30 US US15/364,841 patent/US10093665B2/en not_active Expired - Fee Related
-
2017
- 2017-11-03 AU AU2017254950A patent/AU2017254950B2/en not_active Ceased
-
2018
- 2018-06-20 JP JP2018116705A patent/JP2018172403A/ja active Pending
- 2018-08-31 US US16/120,073 patent/US20180370960A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CL2011001658A1 (es) | Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor. | |
ECSP12011659A (es) | Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
UY30500A1 (es) | Compuestos de azabencimidazolilo | |
AR077765A1 (es) | Inhibidores de los virus flaviviridae | |
ECSP12011935A (es) | Triazolopiridinas | |
ECSP11011398A (es) | Inhibidores de beta-secretasa | |
CU20110235A7 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
GT201100127A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 | |
AR062397A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis | |
CO6351777A2 (es) | Compuestos de tetraciclina sustituidod con fluor en c7 | |
ECSP12012338A (es) | Triazolopiridinas sustituidas | |
AR051043A1 (es) | Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona | |
AR069508A1 (es) | Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento | |
AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas | |
ECSP10010576A (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
CO6321280A2 (es) | Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
AR077869A1 (es) | Forma cristalina de tiazolpirrolidin propionamida como inhibidor de la proteina de apoptosis: formulaciones farmaceuticas | |
AR077692A1 (es) | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo | |
ECSP11011053A (es) | [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos | |
CY1118132T1 (el) | ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ | |
ATE530172T1 (de) | Pharmazeutische formulierungen mit clopidogrel | |
CL2012000102A1 (es) | Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras. | |
GT200500267A (es) | Uso de epotilonas en el tratamiento de metastasis en hueso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |